Martin Brenner

Martin Brenner


Martin Brenner is CEO and CSO of iBio. IBio uses its AI drug discovery platform to tackle complex and challenging drug targets with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise. Martin is a seasoned executive and drug hunter with a unique journey spanning electrical engineering to veterinary medicine to scientific leadership roles.

He has led drug discovery teams at several top global pharma companies, including Eli Lilly, Pfizer, AstraZeneca, and Merck. Prior to his current role at iBio, Martin was VP and head of R&D at Stoke Therapeutics, CSO at Recursion, and CSO at Phoenix, which was eventually acquired by Ligon Pharmaceuticals.

Martin Brenner - iBio - Part 3

Transitioning from Big Pharma to Biotech Startups | Lessons in Flexibility, Resilience, & Adaptability | Challenging Long-Held Beliefs in Drug Discovery | The Evolution & Future of iBio

Martin Brenner - iBio - Part 2

Autonomy at Eli Lilly vs. Structure at Pfizer | Transitioning from AstraZeneca to Merck | Joys & Challenges When Relocating for Work | A Biotech Vision Leading to an Exit From Big Pharma

Martin Brenner - iBio - Part 1

How Childhood Influences Shape Career Paths | Unexpected Crossovers Between Engineering & Veterinary Clinics | Eli Lilly Nurturing His Professional Development | Communication Can Make or Break Leadership

Keep Up with The Biotech Startups Podcast

Start listening to TBSP episodes on your favorite platform.  Subscribe to stay up to date on new episodes.

A hand holding a bell